Filing Flows › Core Laboratories (CLB) › Q2 2026
Core Laboratories (CLB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Core Laboratories (CLB) reported revenue of $125M for the second quarter 2026 (Q2 2026), -4% from a year earlier and +2% from the quarter before. Operating margin was 7.3%, net earnings $6.0M (4.8% of revenue).
Core Laboratories, Q2 2026: revenue $125M (-4% year over year), operating margin 7.3%, net earnings $6.0M, operating cash flow $7.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $125M | +2% | -4% |
| Operating profit | $9.2M | +385% | -40% |
| Net earnings | $6.0M | — | -44% |
| Operating cash flow | $7.8M | +97% | -44% |
| Free cash flow | $3.1M | — | — |
What changed
Revenue was $124.6M in Q2 2026, down 4% year over year and up 2% from the previous quarter. Service was the largest line at 76% of revenue. Product lost $3.6M year over year (down 11%), 65% of the total change.
Operating profit was $9.2M, a 7.3% margin (down 4.4 points year over year). Total costs grew 1% against a revenue fall of 4%. The fastest-growing cost line was Other operating costs (+346%). Net earnings were $6.0M, down 44% year over year ($5.8M including minority interests, which bore $158K of losses). The effective tax rate was 8.0%.
Operating cash flow was $7.8M (down 44% year over year), 135% of net income including minority interests. Non-cash charges added back $3.8M of depreciation and amortization and $902K of share-based compensation. Working capital and other items used $2.7M. After capital expenditures - operations ($4.7M), free cash flow as the company reports it was $3.1M.
Questions
What was Core Laboratories' revenue in the second quarter 2026?
Core Laboratories (CLB) reported revenue of $125M for the second quarter 2026 (Q2 2026), -4% from a year earlier and +2% from the quarter before.
Was Core Laboratories profitable in the second quarter 2026?
Operating profit was $9.2M (7.3% of revenue) and net earnings $6.0M.
Source: Core Laboratories 10-Q on SEC EDGAR.